Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China

• Main Authors: Xiaojie Huang (Author), Liumei Xu (Author), Lijun Sun (Author), Guiju Gao (Author), Weiping Cai (Author), Yanfen Liu (Author), Haibo Ding (Author), Hongxia Wei (Author), Ping Ma (Author), Min Wang (Author), Shuiqing Liu (Author), Yaokai Chen (Author), Xiaohong Chen (Author), Qingxia Zhao (Author), Jianhua Yu (Author), Yuxia Song (Author), Hui Chen (Author), Hao Wu (Author), Shanfang Qin (Author), Linghua Li (Author)
• Format: Book
• Published: Frontiers Media S.A., 2019-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The World Health Organization guidelines recommend lopinavir/ritonavir (LPV/r) as a second-line antiretroviral therapy (ART) for HIV-infected adults in middle-income and low-income countries as a protease inhibitor boost based on clinical trials; however, the real-world safety and efficacy remain un...